Latest news with #Shire
Yahoo
3 days ago
- Entertainment
- Yahoo
Phoenix Fan Fusion schedule: How to see Hayden Christensen and all the huge stars
There is a lot to get excited about when it comes to Phoenix Fan Fusion 2025, the annual comic con and pop culture celebration. Taking place Friday through Sunday, June 6-8, at the Phoenix Convention Center downtown, Fan Fusion is an outpouring of geek culture no matter whether you call the Shire, the T.A.R.D.I.S or a spaceship your home. Perhaps the most exciting part of Phoenix Fan Fusion is the celebrity guests and this year is one for the history books, with big names like Hayden Christensen, Marisa Tomei, Elijah Wood, Rainn Wilson, Katey Sagal, Manny Jacinto and many more. Here are the biggest celebrity guests coming to Phoenix Fan Fusion 2025. Hayden Christensen is best known for playing Anakin Skywalker, The Chosen One meant to bring peace and balance to the Star Wars galaxy but who ultimately fell to the Dark Side and became the iconic villain Darth Vader. He recently reprised his role in the Disney+ television series "Ahsoka" and "Obi-Wan Kenobi." Christensen will be at Fan Fusion all weekend. Special packages, autographs and photo ops will be available. Check the website for pricing. Looks like the entire Shire, plus some, will be at Phoenix Fan Fusion 2025. Frodo actor Elijah Wood, Samwise actor Sean Astin, Merry actor Dominic Monaghan, Pippin actor Billy Boyd and Gimli actor John Rhys-Davies will all be in attendance. Wood's autograph is $100 and a photo op is $100; he will be there June 6-7. Astin's, Monaghan's and Boyd's autographs are $80 each and photo ops are $100 each. Astin will attend June 6; Monaghan and Boyd will be there June 6-7. Rhys-Davies' autograph is $100, a photo op is $120 and he'll be there June 6. For nine seasons, you watched him play Dwight Schrute, the ever loyal and quirky assistant to the regional manager on NBC's "The Office." He also has starred in "House of 1,000 Corpses," "Star Trek: Discovery" and "The Meg." Wilson's autograph is $100, a photo op is $110 and he will be there on June 8. Pegg is known for co-writing and starring in the title role of the 2004 zombie comedy "Shaun of the Dead." His credits in the geek fandom are extensive, with roles in "Doctor Who," "Star Trek" and "Star Wars: The Force Awakens," not to mention playing Benji Dunn in the "Mission: Impossible" franchise. Pegg's autograph is $85, a photo op is $75 and he will be there on June 7. Cox is best known as Matt Murdock aka Daredevil in seven projects in the Marvel Cinematic Universe, including the 2015-2018 television series "Daredevil" and the 2025 series "Daredevil: Born Again." Cox's breakout role was playing the lead in the 2007 romantic fantasy adventure film "Stardust" opposite Claire Danes, and he had a prominent role in "The Theory of Everything" before landing the role of Daredevil in 2014. Cox's 8x10 autograph is $125, a premium autograph is $130, a photo op is $130 and he will be there on June 7. Best known as the Silent Bob half of the wacky acting duo of Jay and Silent Bob, actor/director Kevin Smith made a legacy of a film he shot inside the convenience store where he was working after hours in the '90s. "Clerks" follows a day in the life of two convenience store clerks as they annoy customers, discuss movies and play hockey on the store roof. He also directed "Dogma" and "Chasing Amy." Smith's autograph is $100, a photo op is $90 and he will be there on June 7. Pop culture fans know Marisa Tomei as Spider-Man Tom Holland's Aunt May in the Marvel Cinematic Universe, but she broke out as a star with her hilarious performance in the 1992 film "My Cousin Vinny," which earned her an Oscar for Best Supporting Actress. Other notable films you can find Tomei include 1992's "Chaplin," 2007's "The Wrestler," 2011's "Crazy, Stupid Love" and 2020's "The King of Staten Island" starring Pete Davidson. Tomei's 8x10 autograph is $100 and everything else is $120. She will be there on June 7. Manny Jacinto began his performing career in hip-hop dancing, but he's proved that shifting to acting was the right move. Jacinto had small roles in TV shows like "Once Upon a Time," "Supernatural" and "Bates Motel" before landing a featured role in 2016's "The Good Place." He played an amateur disc jockey who won viewers' affections with his immature, simple, yet kindhearted nature. Most recently, Jacinto starred as Qimir, known as the Stranger, who is the apprentice of Sith Lord Darth Plagueis in the 2023 Star Wars series "The Acolyte" on Disney+. Jacinto's autograph is $70, a photo op is $85 and he will be there on June 7-8. Generations of fans recognize Katey Sagal for her iconic voice as the one-eyed, purple-haired Leela on the animated series "Futurama," her satirized version of a housewife in "Married With Children" that aired from 1987-1997 and her portrayal of Gemma Teller Morrow on the biker drama "Sons of Anarchy," for which she won a Best Actress Golden Globe. Sagal's 8x10 autograph is $100, a selfie is $90, a photo op is $100 and she will be there June 6-8. Maybe you know Ron Perlman as Hellboy from the 2004 film of the same name and its 2008 sequel "Hellboy II: The Golden Army." Gamers will recognize his voice narrating the post-apocalyptic game series Fallout or as Lord Hood in Halo 2 and Halo 3. Perlman is also known for his pivotal role as Clay Morrow, president of the Sons of Anarchy Motorcycle Club Redwood Original in the hit FX series "Sons of Anarchy." Perlman's autograph is $60, a photo op is $70 and he will be here June 6-8. When: 8:30 a.m.-11:30 p.m. Friday-Saturday, June 6-7; 9 a.m.-5 p.m. Sunday, June 8. Where: Phoenix Convention Center, 100 N. Third St. Admission: $44-$595, plus tax and fees; free for age 12 and younger. Details: Meredith G. White covers entertainment, art and culture for The Arizona Republic and She writes the latest news about video games, television and best things to do in metro Phoenix. (This story has been updated with a new photo gallery.) This article originally appeared on Arizona Republic: Fan Fusion 2025: Biggest celebs at Phoenix Convention Center
Yahoo
28-05-2025
- Business
- Yahoo
enGene Names Amy Pott as Chief Global Commercialization Officer
BOSTON & MONTREAL, May 28, 2025--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal cohort of the LEGEND trial. "Amy brings a unique combination of P&L, full commercialization, gene therapy, deep analytics, and global experience to enGene," said enGene CEO, Ron Cooper. "We are thrilled to welcome Amy as our Chief Global Commercialization Officer and believe her leadership and track record of success will be a tremendous asset in preparing and executing the planned launch of detalimogene." Ms. Pott joins enGene from Astellas Pharma, where she most recently served as Senior Vice President (SVP), Strategic Brand Marketing, Ophthalmics and Rare Diseases, and previously as Head of Commercial, Gene Therapies. Prior to Astellas, she was President, North America for Swedish Orphan Biovitrum, and Global Vice President (GVP) U.S. Franchise Head for Internal Medicine and Oncology, as well as GVP, U.S. Commercial Operations at Shire. Before joining Shire, Ms. Pott was Vice President, Strategy, Planning and Analytics at Baxalta, Inc. Ms. Pott holds a Master of Science in European Studies from the London School of Economics and a Bachelor of Arts in History from the University of Bristol. "I am excited to join enGene at such a pivotal moment in its journey," said Ms. Pott. "I look forward to working with this talented team to advance the mission to help transform the treatment landscape for bladder cancer patients with our innovative genetic medicine." About Detalimogene Detalimogene is a novel, investigational, non-viral genetic medicine for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumor immune response. Detalimogene was developed using the Company's Dually Derivatized Oligochitosan® (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially overcome the limitations of viral-based gene therapies, simplify safe handling and cold storage complexities, and streamline both manufacturing processes and administration paradigms. Detalimogene has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC with or without resected papillary tumors who are unable to undergo cystectomy. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. To learn more, please visit and follow us on LinkedIn, X and BlueSky. Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's management teams' expectations, hopes, beliefs, intentions, goals, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate", "appear", "approximate", "believe", "continue", "could", "estimate", "expect", "foresee", "intends", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would", and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: our plans regarding the timing of our planned BLA submission to the Food and Drug Administration and our expectations as to the timing and anticipated results of the LEGEND study, the future growth of enGene, the potential benefits of detalimogene, and the potential benefits of medicines developed with the DDX platform. Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company's clinical development plans and ability to secure regulatory approval on anticipated timelines, and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission ("SEC") on EDGAR, including those described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2024 (copies of which may be obtained at or You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. View source version on Contacts For media contact: media@ For investor contact: investors@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
enGene Names Amy Pott as Chief Global Commercialization Officer
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or 'enGene' or the 'Company'), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal cohort of the LEGEND trial. 'Amy brings a unique combination of P&L, full commercialization, gene therapy, deep analytics, and global experience to enGene,' said enGene CEO, Ron Cooper. 'We are thrilled to welcome Amy as our Chief Global Commercialization Officer and believe her leadership and track record of success will be a tremendous asset in preparing and executing the planned launch of detalimogene.' Ms. Pott joins enGene from Astellas Pharma, where she most recently served as Senior Vice President (SVP), Strategic Brand Marketing, Ophthalmics and Rare Diseases, and previously as Head of Commercial, Gene Therapies. Prior to Astellas, she was President, North America for Swedish Orphan Biovitrum, and Global Vice President (GVP) U.S. Franchise Head for Internal Medicine and Oncology, as well as GVP, U.S. Commercial Operations at Shire. Before joining Shire, Ms. Pott was Vice President, Strategy, Planning and Analytics at Baxalta, Inc. Ms. Pott holds a Master of Science in European Studies from the London School of Economics and a Bachelor of Arts in History from the University of Bristol. 'I am excited to join enGene at such a pivotal moment in its journey,' said Ms. Pott. 'I look forward to working with this talented team to advance the mission to help transform the treatment landscape for bladder cancer patients with our innovative genetic medicine.' About Detalimogene Detalimogene is a novel, investigational, non-viral genetic medicine for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumor immune response. Detalimogene was developed using the Company's Dually Derivatized Oligochitosan® (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially overcome the limitations of viral-based gene therapies, simplify safe handling and cold storage complexities, and streamline both manufacturing processes and administration paradigms. Detalimogene has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC with or without resected papillary tumors who are unable to undergo cystectomy. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. About enGene enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. To learn more, please visit and follow us on LinkedIn, X and BlueSky. Forward-Looking Statements Certain statements contained in this press release may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and 'forward-looking information' within the meaning of Canadian securities laws (collectively, 'forward-looking statements'). enGene's forward-looking statements include, but are not limited to, statements regarding enGene's management teams' expectations, hopes, beliefs, intentions, goals, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate', 'appear', 'approximate', 'believe', 'continue', 'could', 'estimate', 'expect', 'foresee', 'intends', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would', and similar expressions (or the negative version of such words or expressions) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements may include, for example, statements about: our plans regarding the timing of our planned BLA submission to the Food and Drug Administration and our expectations as to the timing and anticipated results of the LEGEND study, the future growth of enGene, the potential benefits of detalimogene, and the potential benefits of medicines developed with the DDX platform. Many factors, risks, uncertainties and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the Company's ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company's clinical development plans and ability to secure regulatory approval on anticipated timelines, and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission ('SEC') on EDGAR, including those described in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2024 (copies of which may be obtained at or You should not place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. enGene anticipates that subsequent events and developments will cause enGene's assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
West Australian
28-05-2025
- Politics
- West Australian
Fitzroy Crossing oval to get security boost with new fence, saving league thousands
Fitzroy Crossing Town Oval will receive a fencing upgrade which will save the Central Kimberley Football and Basketball League around $12,000 on security for the season's finals. The Shire of Derby-West Kimberley has received $2.5 million in State funding for stage two of the Fitzroy Crossing Recreation Precinct Upgrade, part of which will go towards palisade fencing. The most recently published council agenda says procurement work will begin on the fencing project and it is expected to be delivered in the coming financial year. Central Kimberley Football and Basketball League football manager Geoff Davis welcomed the update on the fence upgrade, and said the project was long overdue. 'This has been promised for the last two years,' Mr Davis, a former shire councillor said. Mr Davis said the current chain mesh fence was inadequate as people could cut through it to get in to watch the finals without paying, or to smuggle in alcohol. 'The impact of people sneaking through the fence means we lose money to run the league,' he said. He said the league spent $12,000 on security for last year's finals to control the fence. News of the fencing upgrade follows the installation of new floodlights last year. Mr Davis was a councillor until February, when a mass resignation led to all council positions being declared vacant. Local Government Minister Hannah Beazley has since appointed Commissioner Jeff Gooding to oversee the council until the October elections. Along with the fencing upgrade, the $2.5 million grant is also earmarked to be used for stage two of a youth precinct development. However, this project is now in doubt for the cash-strapped council. In a report in the council agenda from May 22, a council staff member said delivery of the youth precinct would depend on future council considerations. 'The Shire may seek to vary the purpose of the funding should it not proceed,' the report said. In a statement, the shire said the youth precinct project included construction of perimeter fencing around the recreation precinct. 'Stage two includes soft landscaping, picnic and seating facilities and then development of specialised play equipment for all age groups and abilities,' it said. 'The tender has been released and the perimeter fencing will proceed in the second part of this year.'
Yahoo
19-05-2025
- Sport
- Yahoo
Andrew Johns' fury after NRL Immortal completely ignored by Newcastle coach
😃 The good: Ronaldo Mulitalo and divisive antics 😔 The bad: Andrew Johns' plea to Adam O'Brien ignored 😡 The ugly: Terrell May's State of Origin snub There are two schools of thought when it comes to Ronaldo Mulitalo. Some fans (mostly from the Shire) love what the Cronulla winger brings to the game, with his all-talking, all-energy approach. Others label him a big-mouth and predict he's set for a big fall when karma pays him a visit. Whatever you think of him, there is no denying Mulitalo's value and contribution to a Sharks side slowly making its way up the table. After his winger spent most of the game getting in the faces of Melbourne players while playing a massive role in Cronulla's five-point win on Saturday night, coach Craig Fitzgibbon defended his man. "Passion's a good word (for him). He's one of those players that's a good barometer for where your team's energy's at and wanting it so bad," Fitzgibbon said. "He wears his heart on his sleeve and is a really passionate player. He sticks up for his teammates and sometimes pushes the boundaries a little bit, but he's one of those guys you want on your team. "He gets in a battle mode and he's hard to control once he gets into that. We love him for that. Sometimes the lines get blurred but he's doing it for his teammates." Nicho Hynes added: "He's awesome, Ronnie, but I'd hate to play against him. He's a pain the backside but he's someone who brings players together. When he crosses that white line, no one's his friend on the opposition team. We love having him." A host of former players are of the opinion he should just shut up and play football. Either way, Ronnie is box office. It's safe to assume Andrew Johns knows a thing or two about Newcastle and halfbacks. So, when the eighth Immortal says the Knights need to bring Jackson Hastings back at No.7 to reboot a season going nowhere, you'd think coach Adam O'Brien would lean in for a listen. Apparently not. Despite his side losing seven of their last eight to slide to slip to 15th on the ladder, the Knights boss dismissed suggestions Hastings should be recalled to the NRL following Friday night's embarrassing defeat to Parramatta. It's only increased speculation Hastings is off with several senior figures at the club and it's his divisive personality – not his football – keeping him anchored in the NSW Cup. Joey could barely contain his anger and frustration. He said: "They've got to work out who their halves are (because) Tyson Gamble's not a halfback, he's a really good 14. One thing about Jackson, he's polarising as we all know, but he can get you around the park. "He'll organise, he can get a game plan on, he kicks well and he brings other players into play. There's rumours about certain feuds and all this, which I couldn't give a rat's about. Whoever's the best No.7, put them in there and leave them there, because there's no stability in the key areas." There is no doubt Terrell May has the ability to play State of Origin. The Tigers prop has all the traits needed to succeed at that level. But you wonder if his chance will ever come given the reputation – warranted or not – he now carries as someone who doesn't buy into team culture. The Roosters have never fully explained why they extended May's contract last year only to flick him months later. No club gets rid of a representative class player like that without very good reason. The Chooks obviously didn't like what they saw away from the football paddock. May was only ever an outside shot at making the Blues side for Origin 1, but did himself no favours with an online chat telling a mate to throw his NSW jersey in the bin after word got around the front-rower would be overlooked. That fired up former Blues skipper and coach Brad Fittler. "(Manly's) Haumole Olakau'atu a couple of years ago did something very similar and last year I went into Manly and he came up and apologised and sat there and just spoke about how he was immature,' Fittler said. "I really respected things he was speaking about and how contrite he was. "I reckon maybe Terrell May should maybe ring Haumole and humble up a little bit. Seriously, what are these blokes thinking? There's people at home who just love this game. They just love it. And you sit there playing a game and all of a sudden you want to just talk like this. How blasé. Pathetic."
